Biopharma Design
Solutions
We are a leading biopharma R&D company that provides access to the best science and has world class in-house drug discovery platform.
Find out more
Down Arrow icon purple
Autoimmune Diseases
Chronic Inflammatory Diseases
CNS 
Oncology
Autoimmune Diseases
Chronic Inflammatory Diseases
CNS 
Oncology
In Silico Modeling
Wet Lab Infrastructure
In Vivo Facility
AI-powered drug discovery
Big Data Analytics
We are experts in designing and optimizing miniproteins for therapeutical purposes.
Miniproteins are short peptides stabilized by disulfide bridges and possess highly useful attributes (e.g. stability, solubility, low immunogenicity) and these features are maintained during the directed evolution.
Learn more
Miniprotein
Autoimmune Diseases
Chronic Inflammatory Diseases
CNS 
Oncology
Autoimmune Diseases
Chronic Inflammatory Diseases
CNS 
Oncology
In Silico Modeling
Wet Lab Infrastructure
In Vivo Facility
AI-powered drug discovery
Big Data Analytics
We are experts in designing and optimizing miniproteins for therapeutical purposes.
Miniproteins are short peptides stabilized by disulfide bridges and possess highly useful attributes (e.g. stability, solubility, low immunogenicity) and these features are maintained during the directed evolution.
Learn more
Our Platform
ai-powered miniprotein platform
Our miniprotein based drug discovery platform uses two proprietary technologies leveraging AI-driven scaffold selection combined with state-of-the-art wet lab screening ensuring exceptional selectivity towards any drug target in a lightning-fast discovery process.
Hit validation in 6 months
Radically lower preclinical development costs
AI-powered de novo scaffold selection for any target
Outstanding affinity with extreme selectivity
See Our Platform
Hit validation in 6 months
Radically lower preclinical development costs
AI-powered de novo scaffold selection for any target
Global view on all binding interactions - no library bias
See Our Platform
Pipeline
Our Pipeline
Our projects are managed applying state-of-the-art project management approach for drug discovery and development.
Project Initiation
Clinical Development
See Our Pipeline
Careers
Join our team
We are constantly looking for world class talent, join us if you want to work in an agile environment to stay ahead of the game in healthcare.
cutting-edge technologies
diverse portfolio
Seasoned team with global expierence
See Vacancies
Resources
Latest News
See All News
Resources
Latest News
See All News
Resources
Latest News
See All News
Team
June 11, 2024
By VRG Therapeutics
VRG Therapeutics among the top 30 startups to participate in the Labena Ventures Accelerator Program!
White arrow icon up and right direction redirecting to Partner with US page
CREATe-1
May 24, 2024
By VRG Therapeutics
Publication - Chemogenetic Inhibition of the Lateral Hypothalamus Effectively Reduces Food Intake in Rats in a Translational Proof-of-Concept Study
White arrow icon up and right direction redirecting to Partner with US page
Conference
May 22, 2024
By VRG Therapeutics
BIO 2024 San Diego
White arrow icon up and right direction redirecting to Partner with US page
Team
May 14, 2024
By VRG Therapeutics
First stage gating meeting of the year
White arrow icon up and right direction redirecting to Partner with US page
Combi-X
VRG-145
April 17, 2024
By VRG Therapeutics
VRG Therapeutics Advances VRG-145
White arrow icon up and right direction redirecting to Partner with US page
Infrastructure
April 11, 2024
By VRG Therapeutics
VRG Tx Launches Its In Vivo R&D Facility!
White arrow icon up and right direction redirecting to Partner with US page
Kv1.3
March 12, 2024
By VRG Therapeutics
Publication - Journal of Biological Chemistry
White arrow icon up and right direction redirecting to Partner with US page
Kv1.3
AI
February 20, 2024
By VRG Therapeutics
Press release: Experimental verification of our AI-powered drug discovery
White arrow icon up and right direction redirecting to Partner with US page
People
January 8, 2024
By VRG Therapeutics
New member to the team: Dr. Zoltán Urbányi
White arrow icon up and right direction redirecting to Partner with US page
People
January 2, 2024
By VRG Therapeutics
New member to the team: Mariann Kremlitzka, PhD
White arrow icon up and right direction redirecting to Partner with US page
Team
June 11, 2024
By VRG Therapeutics
VRG Therapeutics among the top 30 startups to participate in the Labena Ventures Accelerator Program!
White arrow icon up and right direction redirecting to Partner with US page
CREATe-1
May 24, 2024
By VRG Therapeutics
Publication - Chemogenetic Inhibition of the Lateral Hypothalamus Effectively Reduces Food Intake in Rats in a Translational Proof-of-Concept Study
White arrow icon up and right direction redirecting to Partner with US page
Conference
May 22, 2024
By VRG Therapeutics
BIO 2024 San Diego
White arrow icon up and right direction redirecting to Partner with US page
Team
May 14, 2024
By VRG Therapeutics
First stage gating meeting of the year
White arrow icon up and right direction redirecting to Partner with US page
Combi-X
VRG-145
April 17, 2024
By VRG Therapeutics
VRG Therapeutics Advances VRG-145
White arrow icon up and right direction redirecting to Partner with US page
Infrastructure
April 11, 2024
By VRG Therapeutics
VRG Tx Launches Its In Vivo R&D Facility!
White arrow icon up and right direction redirecting to Partner with US page
Kv1.3
March 12, 2024
By VRG Therapeutics
Publication - Journal of Biological Chemistry
White arrow icon up and right direction redirecting to Partner with US page
Kv1.3
AI
February 20, 2024
By VRG Therapeutics
Press release: Experimental verification of our AI-powered drug discovery
White arrow icon up and right direction redirecting to Partner with US page
People
January 8, 2024
By VRG Therapeutics
New member to the team: Dr. Zoltán Urbányi
White arrow icon up and right direction redirecting to Partner with US page
People
January 2, 2024
By VRG Therapeutics
New member to the team: Mariann Kremlitzka, PhD
White arrow icon up and right direction redirecting to Partner with US page
Team
June 11, 2024
By VRG Therapeutics
VRG Therapeutics among the top 30 startups to participate in the Labena Ventures Accelerator Program!
White arrow icon up and right direction redirecting to Partner with US page
CREATe-1
May 24, 2024
By VRG Therapeutics
Publication - Chemogenetic Inhibition of the Lateral Hypothalamus Effectively Reduces Food Intake in Rats in a Translational Proof-of-Concept Study
White arrow icon up and right direction redirecting to Partner with US page
Conference
May 22, 2024
By VRG Therapeutics
BIO 2024 San Diego
White arrow icon up and right direction redirecting to Partner with US page
Team
May 14, 2024
By VRG Therapeutics
First stage gating meeting of the year
White arrow icon up and right direction redirecting to Partner with US page
Combi-X
VRG-145
April 17, 2024
By VRG Therapeutics
VRG Therapeutics Advances VRG-145
White arrow icon up and right direction redirecting to Partner with US page
Infrastructure
April 11, 2024
By VRG Therapeutics
VRG Tx Launches Its In Vivo R&D Facility!
White arrow icon up and right direction redirecting to Partner with US page
Kv1.3
March 12, 2024
By VRG Therapeutics
Publication - Journal of Biological Chemistry
White arrow icon up and right direction redirecting to Partner with US page
Kv1.3
AI
February 20, 2024
By VRG Therapeutics
Press release: Experimental verification of our AI-powered drug discovery
White arrow icon up and right direction redirecting to Partner with US page
People
January 8, 2024
By VRG Therapeutics
New member to the team: Dr. Zoltán Urbányi
White arrow icon up and right direction redirecting to Partner with US page
People
January 2, 2024
By VRG Therapeutics
New member to the team: Mariann Kremlitzka, PhD
White arrow icon up and right direction redirecting to Partner with US page
Slider move or slide items to left purple arrow icon
Slider move or slide items to right purple arrow icon
Team
June 11, 2024
By VRG Therapeutics
VRG Therapeutics among the top 30 startups to participate in the Labena Ventures Accelerator Program!
White arrow icon up and right direction redirecting to Partner with US page
CREATe-1
May 24, 2024
By VRG Therapeutics
Publication - Chemogenetic Inhibition of the Lateral Hypothalamus Effectively Reduces Food Intake in Rats in a Translational Proof-of-Concept Study
White arrow icon up and right direction redirecting to Partner with US page
Conference
May 22, 2024
By VRG Therapeutics
BIO 2024 San Diego
White arrow icon up and right direction redirecting to Partner with US page
Team
May 14, 2024
By VRG Therapeutics
First stage gating meeting of the year
White arrow icon up and right direction redirecting to Partner with US page
Combi-X
VRG-145
April 17, 2024
By VRG Therapeutics
VRG Therapeutics Advances VRG-145
White arrow icon up and right direction redirecting to Partner with US page
Infrastructure
April 11, 2024
By VRG Therapeutics
VRG Tx Launches Its In Vivo R&D Facility!
White arrow icon up and right direction redirecting to Partner with US page
Kv1.3
March 12, 2024
By VRG Therapeutics
Publication - Journal of Biological Chemistry
White arrow icon up and right direction redirecting to Partner with US page
Kv1.3
AI
February 20, 2024
By VRG Therapeutics
Press release: Experimental verification of our AI-powered drug discovery
White arrow icon up and right direction redirecting to Partner with US page
People
January 8, 2024
By VRG Therapeutics
New member to the team: Dr. Zoltán Urbányi
White arrow icon up and right direction redirecting to Partner with US page
People
January 2, 2024
By VRG Therapeutics
New member to the team: Mariann Kremlitzka, PhD
White arrow icon up and right direction redirecting to Partner with US page
Slider move or slide items to left purple arrow icon
Slider move or slide items to right purple arrow icon
Learn More
Million ways to improve life
Learn More
Million ways to improve life